Plain-English translation of NCT06280105 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications—cadonilimab and regorafenib—in people with advanced liver cancer that has stopped responding to earlier treatment (camrelizumab plus apatinib). The study wants to see whether this new drug combination can be more effective and what side effects people might experience.
When liver cancer stops responding to initial treatment, doctors need other options to help patients. This trial exists to find out whether this new medication combination could work for people in that difficult situation.
You likely qualify if…
You likely don't qualify if…
You would receive the two medications as part of this trial—likely through regular clinic visits where doctors monitor how you're responding and check for side effects. The study will evaluate how well the treatment works and track your health over time. You'll need to have blood tests and imaging scans to measure whether your cancer is shrinking or growing.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Enrollment target
~40 participants
Started
March 2024
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.